News > Olaparib well tolerated in people with early-stage BRCA+, HER2- disease

Olaparib well tolerated in people with early-stage BRCA+, HER2- disease

When given after chemotherapy, the PARP inhibitor extended disease-free time, did not impact quality of life or delay recovery

general_content


Early results of a quality-of-life study presented on December 10 at the San Antonio Breast Cancer Symposium found that olaparib did not worsen or prolong side effects when given after chemotherapy for BRCA+, HER2-, high-risk, early-stage breast cancer.

Background



Around 5 to 10  percent of breast cancers are linked to changes in the BRCA 1 or 2 genes. These changes (mutations) are passed down through families. Genetic testing is used to identify people who have the genetic mutation (described as BRCA+). People who are BRCA+ have a higher risk of breast, ovarian, pancreatic, and prostate cancers.



Research focuses on preventing, finding early, and treating BRCA+ cancers. Medicines showing the most success are PARP inhibitors, a type of targeted therapy.



In 2018, the U.S. Food and Drug Administration approved the PARP inhibitor olaparib (Lynparza) for BRCA+, HER2- metastatic breast cancer. It was the first medicine approved specifically for BRCA+ cancer. This approval was based on the phase III OlympiAD trial of people with BRCA+ metastatic breast cancer.



In 2021, early results from the phase III OlympiA trial showed that olaparib given after chemotherapy extended the time participants were disease-free. This trial included people with BRCA+, HER2-, high-risk, early-stage cancer.



Chemotherapy works by attacking fast-growing cancer cells. In doing so, it can kill healthy cells sometimes causing side effects like hair loss, mouth sores, nausea, and fatigue. In people with early-stage breast cancer, fatigue can be very debilitating and delay recovery by one to two years. The study team looked at whether the addition of olaparib would lengthen the recovery time even more.

Results



Researchers looked at the impact of olaparib after standard treatment for high-risk, early-stage BRCA+ breast cancer on quality of life. The OlympiA trial participants completed surveys at the start of the study and again following treatment with olaparib or a placebo. The results are based on patient reported outcomes (PRO).



The OlympiA trial had 1,836 participants. Of these, 1,535 make up the quality-of-life study group. Eighty-five were excluded for lack of consent, failure to start treatment, and related reasons. An additional 216 did not complete follow-up surveys. The group was representative of the larger study in age, race, and geography.



In general, olaparib was well tolerated. People taking olaparib had slightly more nausea and vomiting at the 6- and 12-month marks. Fatigue was slightly higher at 6 and 12 months as well, but not enough to be considered clinically meaningful. There was no difference in any of these symptoms at 18 and 24 months. Differences were also not seen in diarrhea, physical functioning, and emotional functioning.

What it means for people with early-stage BRCA+, HER2- disease



We already knew that olaparib after chemotherapy had medical benefit. Now we know it is well tolerated by patients and does not affect quality of life in a way that delays recovery. This is significant news for this high-risk group for whom recurrence is a major concern.



This study had some limitations. For example, we do not know anything about the 216 people who did not participate in follow-up. It is possible they were sicker or in some way unlike the study group.



The study also did not address all quality-of-life topics of interest to women with BRCA-driven early-stage cancer, many of whom are younger. Final results of this research are still to come. Hopefully we will learn more about the possible impact on fertility, sexual health, and other priority concerns.

related_resources_article_carousel

Related resources

Targeted therapy for hormone receptor-positive breast cancer

02/12/24 | BY: Sameer Gupta

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy, including CDK 4/6 inhibitors.

Read More
 | 12 Min. Read

Capivasertib

02/03/24 | BY: Sameer Gupta

Capivasertib (Truqap) is a targeted therapy used to treat hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancers that test positive for certain gene mutations

Read More
 | 9 Min. Read |

Abemaciclib

12/01/23 | BY: Sameer Gupta

Abemaciclib (Verzenio) is a targeted therapy approved by the Food and Drug Administration to treat hormone receptor-positive breast cancer.

Read More
 | 8 Min. Read |

Trastuzumab

11/01/23 | BY: Debu Tripathy

Trastuzumab (Herceptin) is the most common medicine used to treat HER2-positive breast cancer. It is a monoclonal antibody, a medicine made in a lab that attacks a specific protein produced on the outside of a cell.

Read More
 | 12 Min. Read |

Targeted therapy

05/01/23 | BY: Stephanie Graff

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help the cells to grow.

Read More
 | 8 Min. Read |

Ribociclib

04/21/23 | BY: Sameer Gupta

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More
 | 6 Min. Read |

Palbociclib

04/19/23 | BY: Sameer Gupta

Palbociclib (Ibrance), a targeted therapy, was the first CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More
 | 5 Min. Read |

Sacituzumab govitecan

02/03/23 | BY: Stephanie Graff

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with several types of metastatic breast cancer.

Read More
 | 5 Min. Read |

Targeted therapy for triple-negative breast cancer

01/01/23 | BY: Zanetta Lamar

Learn more about the different classes of targeted therapies for triple-negative breast cancer, the tumor biomarkers that tell us who may benefit from them, and how they work.

Read More
 | 4 Min. Read |

Trastuzumab deruxtecan

12/19/22 | BY: Pallav K. Mehta

Trastuzumab deruxtecan (Enhertu) is an antibody drug conjugate approved to treat people with metastatic, HER2-positive, hormone receptor-negative breast cancer that has grown after at least two past treatments.

Read More
 | 4 Min. Read
about_this_page_tabbed_module
About this page
Glossary
About LBBC

Jamie Kudera

Placeholder silhouette
  • Has been a contributor to LBBC since 2021
  • Reports on major scientific meetings and works to ensure LBBC's web content is current

Tagged:

Was this page helpful?

Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.